FDA 483 OBSERVATION · #331 OF 1,000 MOST-CITED
General responsibilities of sponsors
FDA cited this observation 84 times across 77 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.9× the rate of the average FDA-cited firm (14.3% vs 7.7%), across 77 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Failure to ensure proper monitoring of the study.
Failure to ensure the study is conducted in accordance with the protocol and/or investigational plan.
Failure to provide investigators with the information needed to conduct the study properly and ensure the study is conducted in accordance with the protocol and/or investigational plan.
Failure to ensure the study is conducted in accordance with the protocol and/or investigational plan.
Failure to ensure the study is conducted in accordance with the protocol and/or investigational plan.
Failure to ensure proper monitoring of the study and ensure the study is conducted in accordance with the protocol and/or investigational plan.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.